Clinical Trials Browser

Phase EARLY_PHASE1 × lenvatinib × 90 days × Clear all

NCT05733715 2026-03-24

Neoadjuvant Pembrolizumab and Lenvatinib for Renal Cell Carcinoma

Phase EARLY_PHASE1 Recruiting

Carcinoma, Renal Cell